secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001770787-25-000011
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q4 revenue down 10% YoY to $165M; FY2024 net loss $182.6M; guidance ~flat
--------------------------------------------------------------------------------

- Q4 2024 revenue $165.0M (-10% YoY); full year $610.8M (-1% YoY).
- Q4 operating loss $49.8M, net loss $49.0M (unchanged YoY).
- Full year 2024 net loss $182.6M, improved from $255.1M loss in 2023.
- FY2025 revenue guidance $610M-$630M (0-3% growth); midpoint implies double-digit growth for Chromium and spatial.
- Cash and securities $393.4M; launched Billion Cells Project with CZI and Ultima Genomics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000011/0001770787-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078725000011/txg-20250212.htm
  HTML page:      https://secwatch.observer/filing/0001770787-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer